Corbus Pharmaceuticals Holdings, Inc.

NasdaqCM:CRBP Stock Report

Market Cap: US$166.8m

Corbus Pharmaceuticals Holdings Past Earnings Performance

Past criteria checks 0/6

Corbus Pharmaceuticals Holdings's earnings have been declining at an average annual rate of -1.8%, while the Biotechs industry saw earnings growing at 36.2% annually. Revenues have been declining at an average rate of 96.1% per year.

Key information

-1.81%

Earnings growth rate

32.72%

EPS growth rate

Biotechs Industry Growth17.04%
Revenue growth rate-96.08%
Return on equity-66.90%
Net Marginn/a
Last Earnings Update31 Mar 2026

Recent past performance updates

Recent updates

Analysis Article • May 20

We're Keeping An Eye On Corbus Pharmaceuticals Holdings' (NASDAQ:CRBP) Cash Burn Rate

We can readily understand why investors are attracted to unprofitable companies. For example, although...
Seeking Alpha • Feb 06

Corbus Pharmaceuticals: Maintaining 'Hold' As Summer 2026 Obesity Data Catalyst Looms

Summary Corbus Pharmaceuticals maintains a 'Hold' rating as it advances CRB-701 for HNSCC and CRB-913 for obesity. CRBP expects to initiate a registrational CRB-701 study in mid-2026 and release 12-week CRB-913 obesity data in summer 2026. Early CRB-913 data show a 2.9% placebo-adjusted mean weight loss at Day 14 with a favorable safety profile and no nausea or vomiting. With $177.8M in cash post-raise, CRBP is funded into 2028, mitigating near-term dilution risk. Read the full article on Seeking Alpha
Analysis Article • Jul 07

Is Corbus Pharmaceuticals Holdings (NASDAQ:CRBP) In A Good Position To Deliver On Growth Plans?

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
Analysis Article • Mar 22

Corbus Pharmaceuticals Holdings (NASDAQ:CRBP) Is In A Good Position To Deliver On Growth Plans

We can readily understand why investors are attracted to unprofitable companies. For example, biotech and mining...
Analysis Article • Dec 06

Companies Like Corbus Pharmaceuticals Holdings (NASDAQ:CRBP) Are In A Position To Invest In Growth

Just because a business does not make any money, does not mean that the stock will go down. For example, Corbus...
Seeking Alpha • Nov 11

Corbus Pharmaceuticals' Sell-Off: Speculative Entry Price In Oncology And Obesity Therapies

Summary Corbus Pharmaceuticals still shows promise, with CRB-701 and CRB-601 advancing in clinical trials and CRB-913 targeting obesity with potentially fewer CNS side effects. Despite early-stage pipeline risks, CRBP's recent sell-off offers a favorable entry point for speculative investors, upgrading my rating from "Hold" to "Speculative Buy." CRBP's valuation is compelling with $159.4 million in liquidity and no significant debt, providing a healthy cash runway. Market concerns over CNS side effects from similar drugs may be overblown. CRB-913's design aims to avoid these issues, enhancing its blockbuster potential. CRB-913, a CB1 inverse agonist for obesity, aims to reduce CNS side effects and presents potential for combination therapy with GLP-1 agonists. Read the full article on Seeking Alpha
Seeking Alpha • Jan 30

Corbus: Ability To Have Best-In-Class Nectin-4 Targeting Drug

Summary Positive results released from phase 1 China study, using CRB-701 for the treatment of patients with metastatic urothelial carcinoma and other nectin-4 positive solid tumors. Trial initiation of phase 1 study, using CRB-701 for the treatment of patients with metastatic urothelial carcinoma and other nectin-4 positive tumors, expected in Q1 of 2024. Additional results from the phase 1 China study, using CRB-701 for the treatment of patients with nectin-4 positive solid tumors, expected at medical meetings throughout 2024. Another ADC, known as PADCEV, is expected to generate $5 billion in projected revenues in urothelial carcinoma. Read the full article on Seeking Alpha
Seeking Alpha • Aug 09

Corbus Pharmaceuticals GAAP EPS of -$0.11

Corbus Pharmaceuticals press release (NASDAQ:CRBP): Q2 GAAP EPS of -$0.11. As of June 30, 2022, the Company has $74 million of cash and investments on hand which is expected to fund operations into the first quarter of 2024, based on the current planned expenditures.

Revenue & Expenses Breakdown

How Corbus Pharmaceuticals Holdings makes and spends money. Based on latest reported earnings, on an LTM basis.

Earnings and Revenue History

NasdaqCM:CRBP Revenue, expenses and earnings (USD Millions)
DateRevenueEarningsG+A ExpensesR&D Expenses
31 Mar 260-85160
31 Dec 250-79150
30 Sep 250-68150
30 Jun 250-58170
31 Mar 250-50170
31 Dec 240-40160
30 Sep 240-39160
30 Jun 240-35140
31 Mar 240-34140
31 Dec 230-45140
30 Sep 230-47150
30 Jun 230-46160
31 Mar 230-51170
31 Dec 220-42190
30 Sep 220-42180
30 Jun 220-35200
31 Mar 220-39200
31 Dec 211-46200
30 Sep 212-44220
30 Jun 213-77240
31 Mar 213-98260
31 Dec 204-111280
30 Sep 206-129290
30 Jun 207-115270
31 Mar 2036-75250
31 Dec 1936-71240
30 Sep 1935-62210
30 Jun 1934-56190
31 Mar 196-70170
31 Dec 185-56130
30 Sep 183-49120
30 Jun 183-41110
31 Mar 182-37100
31 Dec 172-3290
30 Sep 173-2990
30 Jun 173-2890
31 Mar 173-2580
31 Dec 162-2060
30 Sep 162-1550
30 Jun 161-1240
31 Mar 161-1040
31 Dec 151-940
30 Sep 150-830

Quality Earnings: CRBP is currently unprofitable.

Growing Profit Margin: CRBP is currently unprofitable.

Free Cash Flow vs Earnings Analysis

Past Earnings Growth Analysis

Earnings Trend: CRBP is unprofitable, and losses have increased over the past 5 years at a rate of 1.8% per year.

Accelerating Growth: Unable to compare CRBP's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: CRBP is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (54.5%).

Return on Equity

High ROE: CRBP has a negative Return on Equity (-66.9%), as it is currently unprofitable.

Return on Assets

Return on Capital Employed

Discover strong past performing companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2026/07/07 04:26
End of Day Share Price 2026/07/07 00:00
Earnings2026/03/31
Annual Earnings2025/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Corbus Pharmaceuticals Holdings, Inc. is covered by 22 analysts. 9 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Kalpit PatelB. Riley Securities, Inc.
Mayank MamtaniB. Riley Securities, Inc.
George ZavoicoB. Riley Securities, Inc.